Introduction:
Market overview:
Segmentation:
Based on technology, the market is categorized into ex-vivo positive selection technology, in-vivo positive selection, negative selection, microchips & single spiral micro channel. CTC enrichment methods have occupied a market revenue share of over 45.0% of the total market it is anticipated that it shall witness lucrative growth over the forecast period and these techniques for CTC detection include enrichment using magnetic beads, centrifugal force, filtration, and other physical properties such as size, density, deformity, and electric charges
Geography: Americas, APAC, EMEA
North America is estimated to witness a high growth rate in this market due to the well-established healthcare infrastructure with high addition of advanced diagnostic technologies and rising
According to publications, Asia Pacific is estimated to witness significant growth over the next decade with a CAGR of around 13.4%, Growth is mainly led by the technologically advanced countries like China & Japan, which are effectively pushing for better techniques to detect and monitor cancer
According to the National Center for Biotechnology Information (NCBI) stated that the projected cases of prostate cancer all over India for the year 2015 were 28,079. Furthermore, the Leukemia & Lymphoma Society estimated that around, 60,300 people are expected to be diagnosed with leukemia in 2018. The significant growth in the population of cancer patients is fueling for the growth of the circulating tumor cells market.
Key Developments:
Report Description: The report covers in-depth analysis of Circulating Tumor Cell (CTC) tests currently in development. The report assesses the pipeline Circulating Tumor Cell (CTC) test by stage of development (early development, pre-clinical, Clinical and In Approval), by application (Breast, Lung, Liver, Colorectal, Prostate, and others). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement patent, and regulatory designations.
The report includes in-depth company profiles of key players in the Circulating Tumor Cell (CTC) test market. The company profile includes key information on the overview, financial highlights, product portfolio, business strategies, and key recent developments.
The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.
Scope:
Our research works on a holistic 360° approach to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involve the following steps:
Data Collation (Primary & Secondary)
In-house Estimation (Based on proprietary databases and Models)
Market Triangulation
Forecasting
Market-related information is assembled from both primary and secondary sources.
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.
Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.
